Immunogenicity and Blocking Efficacy of Norovirus GII.4 Recombinant P Protein Vaccine

Figures

• 

  Figure 1. SDS-PAGE results of NoV recombinant P protein. (A) Lanes 1 and 2 are bacterial proteins, lanes 3 and 4 are the enzymatic supernatant, and lane 5 is the protein marker. (B) Lanes 1, 2, and 3 are eluents 1,2, and 3 through the Ni column, and lanes 4, 5, and 6 flow through the liquid. Lines 7 and 8 are bacterial proteins. Line 9 is the protein marker.

• 

  Figure 2. ELISA detected the binding capacity of recombinant P protein to HBGAs. “*” indicates p value < 0.05.

• 

  Figure 3. Blocking effect of the neutralizing antibody to HuNoV. Neutralizing antibodies blocked (A) the binding of recombinant P protein to HBGAs and (B) the binding of HuNoV to HBGAs. “*” indicates p value < 0.05.

• 

  Figure 4. Cytopathic effects of MNV infection in RAW264.7 cells. (A) Vacuoles and nuclear pyknosis, (B) infection of nearby cells, (C) a large amount of cell nuclear pyknosis and cell death, and (D) cell shrinkage and fragmentation. Red arrows indicate the vacuoles of cells. Red frames indicate the sites of cytopathic effects.

• 

  Figure 5. Viral loading in RAW264.7 after blocking with neutralizing antibody. (A) Standard curve of MNV viral loading. (B) Protective efficacies of neutralizing antibodies with different titers. “*” indicates p value < 0.05.